EXACT Sciences

Yahoo Finance • 3 months ago

FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize unnecessary follow-up colonoscopies by reducing... Full story

Yahoo Finance • 4 months ago

Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory

We came across a bullish thesis on Aldeyra Therapeutics Inc (ALDX) on ValueInvestorsClub by MrStingy. In this article we will summarize the bulls' thesis on ALDX. Aldeyra Therapeutics shares were trading at $4.15 when this thesis was publi... Full story

Yahoo Finance • 5 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood is having another rough year. The largest of the Ark Invest exchange-traded funds is down 14% this year in an otherwise buoyant year for growth investors. The fund is down 72% since peaking in early 2021. As the founder, CEO, a... Full story

Yahoo Finance • 6 months ago

Is It Time to Buy May's Worst-Performing Nasdaq Stocks?

Software stocks had a terrible time in May. The majority of last month's worst-performing shares were software providers. This is notable considering that these rapid-growth stocks rarely go on sale. But it's not just high-flying software... Full story

Yahoo Finance • 7 months ago

Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript

Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript May 8, 2024 Exact Sciences Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator:... Full story

Yahoo Finance • 8 months ago

Here’s Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to a... Full story

Yahoo Finance • 10 months ago

Exact Sciences Announces Fourth Quarter 2023 Results

Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis,... Full story

Yahoo Finance • 10 months ago

Top 11 CRISPR Stocks To Invest In

In this article, we discuss the top 11 CRISPR stocks to invest in. If you want to skip our discussion of the gene editing industry, head directly to Top 5 CRISPR Stocks To Invest In. Genome editing refers to a set of technologies enabling... Full story

Yahoo Finance • last year

1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark Invest

Scientist injecting samples into test tubes Over the past decade, Ark Investment Management has established its niche on Wall Street by making sizable investments in disruptive and groundbreaking technologies. These include genomic resear... Full story

Yahoo Finance • last year

Ark Invest Stock Portfolio: 16 Biggest Positions

In this article, we discuss the 16 biggest positions in the ARK Invest portfolio. If you want to read about some more stocks in the ARK Invest portfolio, go directly to Ark Invest Stock Portfolio: 5 Biggest Positions. Catherine D. Wood, a... Full story

Yahoo Finance • last year

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates New concordance analysis supporting the generation of Oncotype DX® results from... Full story

Yahoo Finance • last year

15 Stocks with Consistent Growth

In this article, we will take a look at the 15 stocks with consistent growth. To skip our analysis of recent market trends, you can go directly to 5 Stocks with Consistent Growth. Growth companies and companies working on disruptive techn... Full story

Yahoo Finance • last year

Ark Invest Stock Portfolio: Top 11 Picks

In this piece, we will take a look at Cathie Wood and Ark Invest's latest stock picks. If you want to skip our introduction to the well known and oft controversial hedge fund boss, then you can skip ahead to Ark Invest Stock Portfolio: Top... Full story

Yahoo Finance • last year

The Exact Sciences Corp (EXAS) Company: A Short SWOT Analysis

Exact Sciences Corp (NASDAQ:EXAS) has seen a 20% increase in revenue in Q3 2023 compared to the same period in 2022. The company has successfully launched the Oncotype DX Breast Recurrence Score test in Japan. Exact Sciences Corp (NASDAQ:E... Full story

Yahoo Finance • last year

Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth

Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock fell late Wednesday. Continue reading... Full story

Yahoo Finance • last year

Exact Sciences Announces Third-Quarter 2023 Results

Reports record revenue, delivers more than a million test results, raises full-year guidance Third-quarter 2023 highlights Total third quarter revenue of $628 million, an increase of 20%, or 23% on a core revenue basis Delivered more tha... Full story

Yahoo Finance • last year

Exact Sciences to participate in November investor conferences

MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited... Full story

Yahoo Finance • last year

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for next-generation Cologuard test expect... Full story

Yahoo Finance • last year

Exact Sciences Corporation (EXAS) Declined on Disappointing Financial Results

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a... Full story

Yahoo Finance • last year

Exact Sciences schedules third quarter 2023 earnings call

MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after... Full story